Additionally, we have previously demonstrated (Donnelly et al., 2014) that wait-start latencies can be used to make informative predictions about the upcoming outcome of a trial.
Across the population of ramping cells recorded in both the mPFC and VS, there were no epochs between wait-start and nose-poking where significant proportions of ramping neurons (either positive and negative) differentiated between correct and premature responses, or where there were significant interactions between the wait-start latency and upcoming outcome (Fig. 5F, H, J and L).
For the PSTH aligned to the start of the trial there were time bins with significant proportions of cells with a negative correlation between firing rate and wait-start latency, a significant, positively valued effect of upcoming trial outcome and a significant, negatively valued interaction between firing rate and ramping around the median wait-start latency for correct trials.
Mention an upcoming event.
Think about the upcoming event.
Become a sponsor for an upcoming event.
Herewith, we confirmed that the peripheral CD4+ T cell compartment cytokine profile is a potential outcome measure in upcoming randomized controlled clinical trials.
The skewing towards an anti-inflammatory cytokine profile supports the evidence on vitamin D as an immune-modulator, and may be used as outcome measure for upcoming randomized placebo-controlled trials.
As observed under standard delay conditions, there were no pre-nose-poke effects of upcoming trial outcome, or trial delay.
These features were then used as independent variables in a logistic regression model to predict upcoming trial outcome (correct or premature responses).
The effect of the wait-start latency on firing rate within each trial was directly measured using a GLM for the firing rate of each cell, using both upcoming trial outcome and wait-start latency as independent variables.
